More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$249372605
EPS
-3.1
P/E ratio
--
Price to sales
18.77
Dividend yield
--
Beta
2.617658
Previous close
$8.31
Today's open
$8.32
Day's range
$7.69 - $8.53
52 week range
$5.50 - $17.96
show more
CEO
Joseph Payne
Employees
111
Headquarters
San Diego, CA
Exchange
NASDAQ Global Market
Shares outstanding
31288909
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced an expanded collaboration with Meiji Seika Pharma Co., Ltd. (“Meiji”), including a $50 million equity investment at an 80% premium. The expanded partnership includes a memorandum of understanding (“MOU”) related to pandemic preparedness and response in Japan and an exclusive.
Business Wire • Nov 16, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call
Arcturus Therapeutics NASDAQ: ARCT expects to complete enrollment in a mid-stage cystic fibrosis study by the end of 2026 and begin dosing a next-generation treatment for a rare liver disorder in the first quarter of 2027, executives said on the company's third-quarter earnings call.
MarketBeat • Nov 6, 2026

Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced its financial results for the quarter ended September 30, 2026, and provided corporate updates. “The third quarter marked a pivotal step forward for our liver therapeutics franchise, with encouraging ARCT-810 Phase 2 results and the introduction of LUNAR 2.0™, our next-genera.
Business Wire • Nov 5, 2026

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.49 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it will release its financial results for the quarter ended September 30, 2026, after the market close on Thursday, November 5th and will also host a conference call and webcast at 4:30 pm Eastern Time on November 5, 2026. Arcturus Therapeutics Third Quarter 2026 Earning.
Business Wire • Oct 26, 2026

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Zacks Investment Research • Sep 28, 2026

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program.
MarketBeat • Sep 25, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
Seeking Alpha • Sep 24, 2026

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company's next-generation mRNA delivery platform, and additional liver pipeline programs. “The ARCT-810 Phase 2 interim results validate Arcturus' m.
Business Wire • Sep 23, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Arcturus Therapeutics Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.